Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $16.7 million.

  • X4 Pharmaceuticals' Accumulated Expenses fell 1437.9% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year decrease of 1437.9%. This contributed to the annual value of $23.0 million for FY2024, which is 7950.22% up from last year.
  • X4 Pharmaceuticals' Accumulated Expenses amounted to $16.7 million in Q3 2025, which was down 1437.9% from $13.1 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Accumulated Expenses ranged from a high of $23.0 million in Q4 2024 and a low of $6.9 million during Q1 2022
  • Its 5-year average for Accumulated Expenses is $13.0 million, with a median of $12.6 million in 2025.
  • As far as peak fluctuations go, X4 Pharmaceuticals' Accumulated Expenses soared by 8503.28% in 2021, and later tumbled by 3576.5% in 2022.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Accumulated Expenses stood at $7.9 million in 2021, then surged by 52.91% to $12.0 million in 2022, then rose by 6.5% to $12.8 million in 2023, then skyrocketed by 79.5% to $23.0 million in 2024, then fell by 27.58% to $16.7 million in 2025.
  • Its Accumulated Expenses stands at $16.7 million for Q3 2025, versus $13.1 million for Q2 2025 and $12.6 million for Q1 2025.